Phase 1 Study of BBT001 in Atopic Dermatitis Patients Initiated by Bambusa Therapeutics
Bambusa Therapeutics has initiated Phase 1 trial of BBT001 in healthy volunteers and adult patients with moderate to severe Atopic Dermatitis.
Asset / Drug
Drug and asset intelligence for BBT001 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.